Skip to main content
Premium Trial:

Request an Annual Quote

MediSapiens, Bluebee Partnering on NGS Analytics

CHICAGO (GenomeWeb) – Biomedical data company MediSapiens is teaming with high-performance genomics analysis and storage provider Bluebee to offer customized analytics for next-generation sequencing data.

Under the partnership, announced Monday, MediSapiens has integrated its Explorer data curation, management, and analytics technology with Bluebee's cloud-based NGS data analysis platform that includes includes the Integrative Genomics Viewer developed by the Broad Institute.

"With the combination of Bluebee's private cloud-based robust and scalable platform for high-speed, configurable data analysis and [the] Explorer platform's capabilities in data curation, management, and interpretation, scientists and clinicians now have a comprehensive integrated solution that will enhance the development of new diagnostics in the research lab and enable improved therapeutic decisions in a clinical setting", Bluebee CEO Hans Cobben said in a statement.

Bluebee is headquartered in Rijswijk, Netherlands. MediSapiens is based in Helsinki, Finland. Both companies run their US operations from Cambridge, Massachusetts.

MediSapiens offers its services on Microsoft's Azure Cloud and other platforms. Among the company's clients is Bayer Healthcare.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.